medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
boston guidanc look risk-adjust manag look
get back track continu see acceler
believ becom import de-risk event
year
quarterli financi break new ground line pre-announc
result organ growth vs mse repres pt
momentum deceler top line estim vs
mse bp gross margin line mse
organ guidanc expect consist week
note delv whether risk-adjust guid reflect
acceler midpoint back-half growth must bp higher
guidanc lower expect may reflect risk adjust
guid well variou dynam explor later well coronaviru impact
note boston exposur china region grow thu
drive bp annual growth guidanc organ china
without impact specif guidanc impli
impact growth reflect neg impact estim
quarterli growth coronaviru impact across coverag see
guidanc achiev beatabl expect boston guid
high end bracket prior model discuss two biggest
chang besid softer first quarter coronaviru like
nomin effect year
boston full year guidanc impli essenti impact coronaviru
extent procedur reschedul impact last longer
expect could still least bp impact year
visibl weak still clear dont consolid
competitor data decemb culprit month continu
find hard materi share shift alon explain miss late decemb
s-icd issu weak transven bulk
purchas price and/or mismodel harder comp could
driver competit note abbott busi improv
point new product issu high power
worth consid whether micra impact contract
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
think fact clearer next quarter assum boston
maintain share high power market lower outlook
growth declin drive bp reduct
corpor growth
model reflect organ growth back half
load first half back half similar
compani saw term cadenc summari growth outlook
segment see exhibit
growth acceler point harder comp comp point
harder boston guidanc still impli point acceler bucket
provid visibl organ incorpor btg vertiflex drive
bp organ pipelin includ polarx ramp follow recent ce
mark exalt-d scale launch ranger dcb us launch drive
essenti off-set challeng compar beyond
watchman flx acur eu spi discov singl use scope bile
duct directsens addit driver net visibl crystal clear
see path boston organ growth acceler path
would brighter come stronger
deep dive guidanc compani guid organ growth
without neg impact coronaviru delta
rang repres headwind viru beyond china
disrupt commentari around endo slower peripher stabl
increment reflect product cadenc endo commerci cross
train tougher comp pi adjust coronaviru impact
midpoint sell day quarter exhibit pt momentum
deceler focal point call would note boston often
guid point deceler forward quarter given
challeng last year point seem odd consid guidanc
seem appropri could perhap prove conserv low-end
regardless becom de-risk event establish
base year answer coronaviru impact also
better sens exalt vertiflex reimburs impact
serv de-risk full year guidanc
evid broader problem field multipl question
topic day convinc challeng year
fraught idiosyncrat issu mesh dcb steril etc clearli
execut issu rel expect guidanc in-lin guidanc
concern us convinc slower start year caus
alarm either digest year highlight deal activ began
earnest deal spread across vertic may
integration/oper strain similar pressur peripher
first quarter also minor manag movement
shawn mccarthi structur heart valv longer compani art
butcher promot evp asia pacif drive david pierc back endo
shepherd exalt urolog transit happen one
hallmark boston success durabl manag promot
within said boston need regain meet-or-beat mental
integr dynam behind ahead remain focus
acceler intact remain overweight favor view boston
continu rest solid triple-threat thesi base above-p organ
growth continu room margin expans flexibl balanc
sheet deploy underpin overweight rate maintain
pt base ep multipl repres premium
larg cap peer set ep given boston attract growth margin
expans prospect leverag profil line high growth
peer abbott
peer top bottom line growth drive posit risk-reward
peer top bottom line growth drive posit risk-reward
price target base multipl
base case ep assum trade larg cap peer
justifi superior emerg growth margin expans
opportun leverag profil line high growth
peer
fire cylind organ growth acceler doubl digiti
pipelin program outperform sale inflect faster expect high
increment profit new growth driver better leverag recent
 acceler margin expans drive high teen greater ep growth
fire cylind
sustain execut support acceler high singl digit large-cap growth
stori recent build pipelin program drive sale compound-annual-growth-rate
oper margin remain track bp annual
improv next sever year drive mid-teen ep growth
base case reflect multipl ep estim larg cap
devic given boston attract growth margin expans leverag
profil line high growth peer like
pressur multipl front acquisit prove less accret organ growth
key pipelin product fail come market tavr fail gain traction
stent price share pressur increas weigh organ
matur pipelin augment
drive sustain hsd organ growth
profil bp annual margin
expans drive mid teen ep growth
support premium valuat peer
revenu growth better
sustain boston shift
faster end market share gain
continu wamgr shift today
margin expans driven
integr oper effici balanc
sheet flexibl improv
boston move past mesh ir litig
pipelin focus expand
higher growth end market wamgr move
long term margin expans target
beyond suggest plenti room
continu margin expans
balanc sheet deploy seen
rapid pace
roll organ close non-cor btg
risk achiev price
achiev lotu expans
increas competit core de
market competit product
failur execut plan pipelin
program integr
million except ep
million
million
million
sale
sale
sale
sale
good sold
plant properti equip net
sale busi
depreci amort
net chang work capit
oper
payment acquisit
proce busi divestitur
payment invest acquisit certain
proce invest collect note receiv
invest
payment conting consider amount
chang long-term debt
chang short-term debt
payment acquisit treasuri stock
use net share settl employe equiti
proce issuanc share common stock
financ
effect foreign exchang rate cash
balanc begin period
balanc end period
